The Yale Club of Los Angeles invites you to join leaders on the forefront of medical innovation from The Lundquist Institute, Bayer Digital, and the Yale School of Medicine for this terrific virtual panel on Wednesday, September 13.
In this virtual session, speakers will focus on innovations in cardiac care and how emerging cardiovascular imaging technology and novel therapies are addressing serious health risks before they become life-threatening. Illnesses covered will include coronary artery disease, vascular disease, and heart disease. The discussion will also explore the role of artificial intelligence. In Q2 2023 alone, there were 8,476 AI patents filed in the medical device industry. In the lead were applications for radiology and cardiology. How is AI being leveraged in this space, and what is the medical community's response?
Panelists:
Dr. Matthew Budoff, investigator and Director of Cardiac CT at The Lundquist Institute, will highlight his work on CT and CAC scanning, and illuminate how existing technology detects and prevents deadly cardiovascular diseases. He will also educate our audience on the importance of proactive scanning and what improvements to CT and CAC scanning lie ahead.
Ms. Hortense Allison, VP and Head of Regulatory Digital at Bayer, will offer perspective on the regulatory landscape and how digital solutions are shaping the future of preventive healthcare and supporting clinicians in diagnostic decision making.
Dr. Albert Sinusas, Professor of Medicine and Director of The Translational Research Imaging Center at Yale School of Medicine, will share his expertise on the application of non-invasive cardiovascular imaging approaches for the assessment of cardiovascular pathophysiology and how multi-modality cardiovascular imaging is helping doctors understand the heart like never before.
Dr. Edward Miller, Associate Professor of Medicine and Vice Chief of Cardiovascular Medicine at Yale School of Medicine, will will focus on imaging of infiltrative cardiomyopathies (cardiac amyloidosis and sarcoidosis) as well as novel hybrid imaging techniques (nuclear + CT) for the diagnosis, prognosis, and treatment response for heart disease.
Q & A session will follow for attendees to engage in the discussion.